| Detected | Trial | Change |
|---|---|---|
| 2026-08-14 | NCT06980116 Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell… · Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. |
Trial sites expanded: 9 -> 17 locations |
| 2026-08-09 | NCT06464861 Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma · Second Affiliated Hospital, School of Medicine, Zhejiang University |
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine |
| 2026-08-08 | NCT04765111 Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma · M.D. Anderson Cancer Center |
date change Primary completion pushed: 2026-08-30 -> 2028-08-30 |
| 2026-08-08 | NCT04765111 Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma · M.D. Anderson Cancer Center |
date change Completion pushed: 2026-08-30 -> 2028-08-30 |
| 2026-08-07 | NCT05006716 A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell… · BeOne Medicines |
Trial sites reduced: 127 -> 114 locations |
| 2026-08-07 | NCT05990465 LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell… · Medical College of Wisconsin |
date change Primary completion pushed: 2026-07 -> 2028-07 |
| 2026-08-07 | NCT05990465 LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell… · Medical College of Wisconsin |
date change Completion pushed: 2027-07 -> 2030-07 |
| 2026-08-06 | NCT07673367 Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma · Vanderbilt-Ingram Cancer Center |
Recruitment opened |
| 2026-08-01 | NCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) · Janssen Research & Development, LLC |
date change Completion moved earlier: 2030-12-31 -> 2029-12-31 |
| 2026-07-31 | NCT07609862 A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies · Guangzhou Lupeng Pharmaceutical Company LTD. |
Recruitment opened |
| 2026-07-31 | NCT07424833 A Study of APG-3288 in Relapsed/Refractory Blood Cancers · Ascentage Pharma Group Inc. |
Recruitment opened |
| 2026-07-31 | NCT07424833 A Study of APG-3288 in Relapsed/Refractory Blood Cancers · Ascentage Pharma Group Inc. |
Trial sites expanded: 2 -> 6 locations |
| 2026-07-30 | NCT05365659 IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas · Iksuda Therapeutics Ltd. |
Primary endpoint(s) modified |
| 2026-07-30 | NCT05365659 IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas · Iksuda Therapeutics Ltd. |
date change Primary completion pushed: 2026-09 -> 2027-09 |
| 2026-07-25 | NCT03478514 Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma · Alliance Foundation Trials, LLC. |
date change Primary completion pushed: 2025-11-10 -> 2025-12-19 |
| 2026-07-23 | NCT01479842 Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma · Kami Maddocks, MD |
date change Primary completion pushed: 2026-07-01 -> 2026-12-01 |
| 2026-07-23 | NCT01479842 Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma · Kami Maddocks, MD |
date change Completion pushed: 2026-09-01 -> 2026-12-01 |
| First Posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-07-22 | NCT07719556 Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With… | The First Affiliated Hospital with Nanjing Medical University NEW | Phase 2 |
| 2026-07-17 | NCT07711327 Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase… | Tina Baykaner NEW | |
| 2026-07-13 | NCT07697339 HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. NEW | Phase 1 |
| 2026-07-06 | NCT07684950 Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After… | Henan Cancer Hospital NEW | Phase 2 |
| 2026-06-29 | NCT07673367 Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma | Vanderbilt-Ingram Cancer Center NEW | Phase 2 |
| 2026-05-27 | NCT07609446 Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma | The First Affiliated Hospital of Soochow University NEW |
| NCT ID | Title | Sponsor | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07264894 | ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a… | Zhengzhou University | Not Yet Recruiting |
| Phase 3 | |||
| NCT06496308 | Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment | Ruijin Hospital | Recruiting |
| NCT06363994 | A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL | InnoCare Pharma Inc. | Recruiting |
| NCT07377578 | A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With… | Guangzhou Lupeng Pharmaceutical Company LTD. | Recruiting |
| NCT06742996 | A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared… | BeOne Medicines | Recruiting |
| NCT01804686 | A Long-term Extension Study of PCI-32765 (Ibrutinib) | Janssen Research & Development, LLC | Recruiting |
| NCT05976763 | Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for… | Alliance for Clinical Trials in Oncology | Recruiting |
| NCT04002297 | A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With… | BeOne Medicines | Active, Not Recruiting |
| NCT03267433 | Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual… | ECOG-ACRIN Cancer Research Group | Active, Not Recruiting |
| Phase 2 | |||
| NCT05992597 | ZR2 Sequential Immunochemotherapy for Newly Treated MCL | Zhejiang Cancer Hospital | Recruiting |
| NCT05833763 | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With… | Australasian Leukaemia and Lymphoma Group | Recruiting |
| NCT06482684 | CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma | Christian Schmidt, MD | Recruiting |
| NCT06341556 | A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients… | Fudan University | Recruiting |
| NCT05910801 | Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory… | Academic and Community Cancer Research United | Recruiting |
| NCT05281809 | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute… | John Lister | Recruiting |
| NCT05635162 | Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma | University College, London | Recruiting |
| NCT06463691 | Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients | Tianjin Medical University Cancer Institute and Hospital | Recruiting |
| NCT06846489 | Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk… | Sun Yat-sen University | Recruiting |
| NCT07199296 | Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell… | Ruijin Hospital | Recruiting |
| NCT04484012 | Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed… | City of Hope Medical Center | Recruiting |
| NCT07285590 | Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in… | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Recruiting |
| NCT05249959 | Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in… | Fondazione Italiana Linfomi - ETS | Recruiting |
| NCT06054776 | Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory… | City of Hope Medical Center | Recruiting |
| NCT07077512 | Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma | Sun Yat-sen University | Recruiting |
| NCT04883437 | Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular… | Emory University | Recruiting |